Please login to the form below

Not currently logged in
Email:
Password:

Galapagos

This page shows the latest Galapagos news and features for those working in and with pharma, biotech and healthcare.

New data keeps AbbVie’s star pipeline therapies on track

New data keeps AbbVie’s star pipeline therapies on track

Meanwhile, Gilead and Galapagos’ filgotinib – an AbbVie cast-off that now looks like the biggest competitive threat to upadacitinib – is also in a phase II trial in atopic dermatitis.

Latest news

More from news
Approximately 6 fully matching, plus 31 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    271. Galapagos/ AbbVie. Agreement extension. Cystic fibrosis alliance for development of a triple combination therapy; increase in milestones from $350m to $600m.

  • Deal Watch December 2015 Deal Watch December 2015

    therapy areas such as oncology and, this month inflammatory disease, following the licensing deal with Galapagos for over $2bn. ... Galapagos (NL). Gilead. Collaboration. licence. JAK1-selective inhibitor, filgotinib in phase II for RA and Crohn's

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    195+. Galapagos/ Charles River. Acquisition of CRO business. Drug discovery services business.

  • Pharma deals during March 2014 Pharma deals during March 2014

    Galapagos decided to sell its BioFocus and Argenta drug discovery service divisions to Charles River during the month so that it could focus on being an R&D company and use

  • Deal Watch table for September 2013 Deal Watch table for September 2013

    423. Galapagos / AbbVie. Global alliance. Novel potentiator / combination therapies in cystic fibrosis focussing on F508del and G551D mutations.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics